Eurofins Scientific


A decent end to FY24: investors jittery with biopharma headwinds

31/01/25 -"During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was attributable to continued weakness in the Biopharma ..."

Pages
55
Language
English
Published on
31/01/25
You may also be interested by these reports :
06/02/25
Securitas had a robust Q4 24 with organic sales growth and improved operating margin, primarily driven by Europe and Ibero-America. In North America, ...

31/01/25
During FY24, Eurofins’ revenue was in line with market expectations, but the EPS and FCF outperformed. The initial knee-jerk reaction was ...

30/01/25
Eurofins has announced a strong close to FY24 – revenue was in line, but the EPS and FCF outperformed. However, the stock price is down 2.5% as ...

28/01/25
In an ad-hoc update, Rentokil reported Q4 FY24 organic revenue growth of 3.0% yoy, in line with market expectations. North America’s organic sales ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO